A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Clinical Oncology

• Publication date

  2018-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2018.36.15_SUPPL.TPS12126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy

  2024cites this paper
• The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

  2024cites this paper
• Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.

  2022cites this paper
• A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)

  2022cites this paper
• Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

  2021influential citation
• Targeting cancer with antibody-drug conjugates: Promises and challenges

  2021cites this paper
• Antibody–Drug Conjugates for Cancer Therapy

  2020cites this paper
• Antibody–Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges

  2020influential citation
• Emerging therapeutic agents for advanced non-small cell lung cancer

  2020cites this paper
• AXL as a Target in Breast Cancer Therapy

  2020cites this paper